Verification evidence is still being completed.
PDF / print export
BioNTech SE
Mainz, Germany
- Verified lead
- Ugur Sahin
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO and Co-Founder
- 2026 technical specialization
- mRNA Immunotherapy
- Review cycle
- May 2026
- Full address
- An der Goldgrube 12, 55131 Mainz, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- BioNTech Management Board page.
- Editorial note
- Commercial GMP mRNA and immunotherapy platform with process trains up to 1,800 L, LNP encapsulation units, and late-stage oncology execution pressure in 2026.
mRNA Immunotherapy
GMP Certified, GCP, GLP
Commercial GMP mRNA and immunotherapy platform with process trains up to 1,800 L, LNP encapsulation units, and late-stage oncology execution pressure in 2026.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Mainz, Germany
BioNTech SE
mRNA Immunotherapy · Commercial Phase
Verified 14 Mar 2026 · 4 sources
mRNAVaccineCommercial
Commercial GMP mRNA and immunotherapy platform with process trains up to 1,800 L, LNP encapsulation units, and late-stage oncology execution pressure in 2026.
Contact & location
- Website
- biontech.com
- [email protected]
- Company page
- Lead
- Ugur Sahin (verified ↗)
- Compliance
- GMP Certified · GCP · GLP
- Last reviewed
- 14 Mar 2026 (4mo ago)
- Scale
- Commercial Phase
- Capabilities
- mRNA Vaccine Development · Cellular Therapy · Infectious Disease Research
- Founded
- 2008
- Headcount
- 5001-10000
mRNA Immunotherapy
Commercial GMP mRNA and immunotherapy platform with process trains up to 1,800 L, LNP encapsulation units, and late-stage oncology execution pressure in 2026.
Related companies
Editorial note
BioNTech remains a flagship German therapeutics node with Ugur Sahin still leading the Management Board while the company prepares a founder-led transition by the end of 2026.
Watch note
BioNTech's FY 2024 update keeps the company on a potential first oncology launch path in 2026 and points to multiple clinical data updates across 2025 and 2026.
Note sourceFULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Verification details
Clinical profileSTATUS: VERIFIED MARCH 2026
Ugur Sahin
CEO and Co-Founder
Full addressAn der Goldgrube 12, 55131 Mainz, Germany
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official BioNTech imprint and corporate documents naming An der Goldgrube 12, Mainz as headquarters.
Open sourceCommercial Phase
Mainz, Germany. mRNA Immunotherapy. Review completed on 14 Mar 2026.
Paul-Ehrlich-Institut (PEI)
GMP Certified, GCP, GLP
Latest public certification
ISO 45001 certificate revision: 11 Feb 2025
BioNTech ISO 45001 certificate.Capabilities
mRNA Vaccine Development
Cellular Therapy
Infectious Disease Research
Sources
The official sources used to verify this profile.
Infrastructure
LNP Encapsulation Units
Automated Bioanalyzers
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
Review log
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
Frequently asked questions
- Where is BioNTech SE located?
- BioNTech SE operates from An der Goldgrube 12, 55131 Mainz, Germany, Mainz, Germany.
- Who runs BioNTech SE?
- BioNTech SE is led by Ugur Sahin, CEO and Co-Founder. Verified 14 Mar 2026.
- What certifications does BioNTech SE hold?
- BioNTech SE is documented under GMP Certified, GCP, GLP.
- What does BioNTech SE do?
- Commercial GMP mRNA and immunotherapy platform with process trains up to 1,800 L, LNP encapsulation units, and late-stage oncology execution pressure in 2026. Core capabilities: mRNA Vaccine Development, Cellular Therapy, Infectious Disease Research.
Editorial context
Related technical briefs
Briefs that name Mainz as a covered market or city.